Buy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026

FomoAnxiety · 2026-03-06T14:43:06+00:00

Top Wall Street Analysts recommend buying three biotech stocks: Cybin, with a potential upside of 857.45%; Metagenomi, with 490.06%; and RegenXBio, offering 266.43%. All stocks have received recent Buy ratings from leading analysts.

FomoAnxiety

2026-03-06 14:43:06

Abstract generation in progress

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts.

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

Cybin HELP -3.37% ▼ – Cybin is a clinical-stage biotech company developing psychedelic-based treatments for mental health conditions like depression and anxiety. Today, H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on the stock with a price target of $95. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 857.45%.

Metagenomi, Inc. MGX +0.62% ▲ – Metagenomi is a biotech company that develops gene-editing tools to help treat genetic diseases. Today, TD Cowen analyst Joseph Thome maintained a Buy rating on the stock. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 490.06%.

RegenXBio RGNX -1.95% ▼ – This is a biotech company that develops gene therapy treatments for genetic diseases using its NAV technology platform. Today, Clear Street analyst William Maughan maintained a Buy rating on the stock with a price target of $45. Interestingly, three out of the four Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 266.43%.

Who Are the Top Analysts?

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes